Skip to Content

Methyl aminolevulinate topical Pregnancy and Breastfeeding Warnings

Methyl aminolevulinate topical is also known as: Metvixia

Medically reviewed on September 11, 2017

Methyl aminolevulinate topical Pregnancy Warnings

FDA pregnancy category: C

Use methyl aminolevulinate topical only if clearly needed and benefit outweighs potential risk.

There are no controlled data in human pregnancy. Intravenous methyl aminolevulinate was teratogenic in rabbits at a dose 926 times the maximum therapeutic human dose (MTHD). Slightly lower fetal body weights and increased incidences of fetuses with jugals connected/fused to maxilla, supernumerary ribs, incompletely ossified cranial bones and other ossification irregularities were noted, as well as maternal toxicity.

See references

Methyl aminolevulinate topical Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Metvixia (methyl aminolevulinate topical)." Galderma Laboratories Inc, Cranbury, NJ.

References for breastfeeding information

  1. "Product Information. Metvixia (methyl aminolevulinate topical)." Galderma Laboratories Inc, Cranbury, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide